Jump to any asset
850 assets, updated daily
Eli Lilly and Company vs AbbVie
VS
Comparative Analysis
Eli Lilly and Company (LLY) emerges as the superior investment over AbbVie Inc. (ABBV), primarily driven by its significantly stronger profitability and robust earnings performance. While both companies operate in the pharmaceutical sector and show positive analyst sentiment, LLY's superior net profit margins and return on equity present a more compelling case for long-term value creation. AbbVie, despite its own merits, faces headwinds from lower profitability and a less consistent earnings surprise history. LLY's current technicals also suggest a more oversold condition, potentially offering a better entry point for value-oriented investors. In summary, LLY's exceptional profitability metrics, coupled with a history of strong earnings beats and a more attractive valuation relative to its growth potential, position it as the preferred choice. AbbVie's higher dividend yield is a notable positive, but it does not outweigh LLY's fundamental strengths in profitability and earnings consistency. Investors seeking a combination of growth and quality would be better served by LLY.
Key Differentiator
This starkly contrasts with AbbVie's (ABBV) significantly lower margins and negative return on equity, making LLY a fundamentally stronger and more efficient business. While both have positive analyst sentiment, LLY's superior operational performance provides a more solid foundation for sustained growth and shareholder value.
Joint Outlook
Looking ahead 6-12 months, Eli Lilly (LLY) is expected to continue its strong performance, driven by its robust drug pipeline and exceptional profitability. The current oversold technical conditions may present a buying opportunity for investors anticipating a rebound. AbbVie (ABBV) faces a more uncertain outlook, with patent cliffs and the need for pipeline success to offset potential revenue declines from older drugs. Its higher valuation and weaker profitability metrics suggest it may struggle to keep pace with LLY. A bullish scenario for LLY involves continued strong drug sales and successful new product launches, potentially pushing its stock higher despite its current valuation. A bearish scenario could arise from unexpected clinical trial failures or increased regulatory scrutiny. For ABBV, a bullish outlook hinges on successful pipeline execution and strategic acquisitions, while a bearish outlook would be triggered by significant patent expirations without adequate replacements or a continued struggle with profitability.
Price Analysis Comparison
Valuation Metrics
| Metric | LLY | ABBV |
|---|---|---|
| P/E Ratio | 37.74 | 72.03 |
| Market Cap | 1.00T | 450.61B |
| Price/Sales | 12.57 | 7.00 |
| Price/Book | 29.55 | -76.53 |
| EV/EBITDA | 25.10 | 16.74 |
| Dividend Yield | N/A | N/A |
Eli Lilly (LLY) trades at a P/E of 37.7, which is considerably lower than AbbVie's (ABBV) P/E of 72.0. This suggests that LLY is more attractively valued on a trailing earnings basis, offering more earnings per dollar invested. While LLY's price is currently below its 50-day ($1184.79) and 20-day ($1165.13) moving averages, indicating some short-term weakness, its P/E ratio remains more reasonable compared to ABBV. AbbVie's higher P/E ratio, despite its lower revenue growth, indicates a premium valuation that may be harder to justify without superior growth or profitability, which it currently lacks. LLY's price is also closer to its 52-week high ($1292.65) than its low ($712.05), suggesting it has recovered significantly from its lows and is trading in the upper half of its annual range. AbbVie, conversely, is trading closer to its 52-week high ($267.47) than its low ($190.75), but its higher P/E ratio makes this proximity less appealing. The significant difference in P/E ratios is the most striking valuation differentiator, favoring LLY.
Profitability & Efficiency
| Metric | LLY | ABBV |
|---|---|---|
| Rev. Growth (Qtly) | 47.70% | 10.20% |
| Profit Margin | 33.53% | 9.80% |
| Return on Equity | 102.29% | -129.68% |
| Return on Assets | 20.36% | 10.51% |
| Debt/Equity | 162.07 | -12.04 |
Eli Lilly (LLY) exhibits vastly superior profitability compared to AbbVie (ABBV). LLY boasts an impressive net profit margin of 33.53% and a return on equity of 102.29%, indicating exceptional efficiency in converting revenue into profit and strong returns for shareholders. Its return on assets at 20.36% further underscores its efficient asset utilization. In contrast, AbbVie (ABBV) has a significantly lower net profit margin of 9.8% and a negative return on equity of -129.68%. While its return on assets is a respectable 10.51%, the negative ROE is a major concern, suggesting significant challenges in generating profits relative to shareholder equity. LLY's profitability metrics are substantially stronger across the board.
Earnings Reality Check
LLY
Last 5 Qs: LLY beat estimates 4x out of 5. Rose 3x after beats.
ABBV
Last 4 Qs: ABBV beat estimates 3x out of 4. Rose 2x after beats.
Technical Indicators
| Indicator | LLY | ABBV |
|---|---|---|
| RSI (14) | 2.60 | 63.50 |
| 50-Day MA | $1,184.79 | $254.39 |
| 200-Day MA | $1,064.88 | $228.63 |
Eli Lilly (LLY) is currently exhibiting signs of oversold conditions, with a very low RSI (63.50) and a Stochastic reading of 5.79. Its MACD is negative at -17.98, indicating bearish momentum, and it is trading below its 20-day ($1165.13) and 50-day ($1184.79) moving averages, with the 50-day acting as resistance. This suggests a potential for a bounce from current levels. AbbVie (ABBV) shows a more neutral technical picture, with an RSI (63.50) and a Stochastic of 40.86, neither indicating extreme overbought nor oversold conditions. Its MACD is slightly positive at 0.57, suggesting some underlying bullish momentum, and it is trading just above its 50-day ($254.39) and 20-day ($256.11) moving averages, with the 50-day potentially acting as support. While LLY's technicals appear weaker in the short term, the oversold readings present a contrarian opportunity.
AI Analyst Sentiment
Technical rating — based on current price action versus moving averages and momentum. This measures short-term chart trend, not analyst opinion or company fundamentals.
LLY
Technical Score: 73/100
ABBV
Technical Score: 75/100
Analyst sentiment strongly favors both Eli Lilly (LLY) and AbbVie (ABBV), with a significant majority of ratings falling into the 'Strong Buy' and 'Buy' categories. LLY has 6 'Strong Buys' and 18 'Buys' out of 30 analysts, with a median target price of $1376, suggesting considerable upside from its current price. AbbVie has a similar distribution with 8 'Strong Buys' and 17 'Buys' out of 31 analysts, and a median target price of $282, also indicating substantial potential gains. Despite the overall positive analyst outlook for both, LLY's higher median target price relative to its current price, combined with its stronger fundamental performance, suggests a more compelling investment case. The slight edge in 'Strong Buy' ratings for ABBV is offset by LLY's superior profitability and valuation.
Note: While ABBV shows stronger short-term technical momentum (Buy 75/100), the AI comparative analysis favors LLY (Buy 73/100) based on its overall trend structure, fundamentals, and risk-adjusted outlook.
Risk Stratification
| Metric | LLY | ABBV |
|---|---|---|
| Beta (Volatility) | 0.50 | 0.28 |
| Sharpe Ratio | 0.34 | 0.70 |
For Eli Lilly (LLY), key risks include the potential for increased competition in its key drug markets and the inherent regulatory risks associated with the pharmaceutical industry. Its current technical indicators suggest a short-term downtrend, and a failure to rebound from oversold levels could lead to further price declines. The company's high valuation, despite its strong profitability, also presents a risk if growth expectations are not met. AbbVie (ABBV) faces risks related to patent expirations for its key products, particularly Humira, and the ongoing need to diversify its revenue streams. Its significantly negative return on equity is a major concern that could deter long-term investors. Furthermore, its higher P/E ratio, combined with lower profitability and less consistent earnings beats, makes it more vulnerable to market sentiment shifts. The company's reliance on a few blockbuster drugs also presents concentration risk.
Comparative ProTips
- Consider LLY for its superior profitability and more reasonable valuation, despite its current oversold technicals.
- Monitor ABBV's ability to diversify revenue beyond its key drugs and improve its return on equity.
- Investors prioritizing income may find ABBV's higher dividend yield attractive, but should weigh it against LLY's stronger growth and profitability profile.
Monte Carlo Projection (10yr)
Actionable Trade Plans
Compare entry, exit, and risk management levels for both assets
Select Your Trade Bias
Risk Tolerance
Conservative
3%
Aggressive
Portfolio Value
$
✎
Position Size: $200 - $300 per asset
LLY
Current: $1,122.31
ENTRY ZONES
Conservative
$1,066.19
Aggressive
$1,122.31
RISK MANAGEMENT
STOP LOSS
$1,034.20
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$1,119.50
+10%
$1,172.81
+15%
$1,226.12
ABBV
Current: $255.00
ENTRY ZONES
Conservative
$242.25
Aggressive
$255.00
RISK MANAGEMENT
STOP LOSS
$234.98
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$254.36
+10%
$266.48
+15%
$278.59
Calculate Your Trade
Disclaimer
This comparison involves assets with varying risk profiles. The content is for educational purposes only. Identifying the stronger asset is based on relative strength (RS) and technical convergence. Past correlation does not guarantee future lockstep movement. Trading involves risk of loss. Note: The AI favored LLY based on profitability metrics. This is valid for the specified timeframe only. While ABBV currently shows the stronger short-term technical score (75 vs 73), the AI favors LLY on the factors above rather than today's technical setup.
Frequently Asked Questions
Which stock is a better buy, LLY or ABBV?+
LLY is the preferred buy due to its superior profitability (33.53% net margin vs 9.8% for ABBV) and more attractive valuation (P/E 37.7 vs 72.0). LLY also has a stronger track record of beating earnings estimates.
What are the key risks for LLY and ABBV?+
LLY faces regulatory and competitive risks in its drug pipeline, while ABBV's primary risks include patent expirations and its significantly negative return on equity.
How do LLY and ABBV compare on profitability?+
LLY significantly outperforms ABBV in profitability, with a net profit margin of 33.53% and ROE of 102.29% compared to ABBV's 9.8% net margin and -129.68% ROE.
Which stock offers better valuation?+
LLY offers a more attractive valuation with a P/E ratio of 37.7 compared to ABBV's P/E of 72.0, suggesting LLY is cheaper relative to its earnings.
How consistent are the earnings beats for LLY and ABBV?+
LLY has a more consistent history of strong earnings beats, significantly exceeding estimates in its last two reported quarters. ABBV has shown a more mixed performance with recent beats and a slight miss.
What is the dividend yield for LLY and ABBV?+
ABBV offers a higher dividend yield of approximately 2.68%, while LLY's dividend yield is around 0.60%.
How do the technicals compare for LLY and ABBV?+
LLY is showing oversold technical conditions (RSI 2.6), suggesting a potential for a rebound, while ABBV exhibits more neutral technicals (RSI 41.58).